This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and CSL Limited Sponsored ADR (CSLLY) have performed compared to their sector so far this year.
New Strong Sell Stocks for August 14th
by Zacks Equity Research
AGO, BATL and CSLLY have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2023.
5 Diverse Medical Stocks to Buy for 2023 and Beyond
by Shaun Pruitt
The top and bottom-line growth make these Zacks Medical stocks very attractive.
What Makes CSL Limited Sponsored ADR (CSLLY) a Good Fit for 'Trend Investing'
by Zacks Equity Research
CSL Limited Sponsored ADR (CSLLY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
CSL Limited Sponsored ADR (CSLLY) Upgraded to Buy: Here's Why
by Zacks Equity Research
CSL Limited Sponsored ADR (CSLLY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Has CSL Limited Sponsored (CSLLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CSLLY) Outperforming Other Medical Stocks This Year?
Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder.